Bard (company): Difference between revisions
No edit summary |
m →History: elimination of marketing terminology |
||
| Line 20: | Line 20: | ||
products = Vascular, Urology, Oncology, and Surgical Specialties | |
products = Vascular, Urology, Oncology, and Surgical Specialties | |
||
homepage = [http://www.crbard.com http://www.crbard.com]}} |
homepage = [http://www.crbard.com http://www.crbard.com]}} |
||
'''C. R. Bard, Inc.''', now branded simply as '''Bard''', headquartered in [[Murray Hill, New Jersey]], USA, is a leading multinational developer, manufacturer, and marketer of |
'''C. R. Bard, Inc.''', now branded simply as '''Bard''', headquartered in [[Murray Hill, New Jersey]], USA, is a leading multinational developer, manufacturer, and marketer of [[medical technologies]] in the fields of [[Vascular]], [[Urology]], [[Oncology]], and [[Surgical]] Specialties. Bard markets its products and services worldwide to [[hospitals]], individual [[health care professionals]], extended care facilities, and alternate site facilities. An [[S&P 500]] company with approximately 14,000 employees in 2015, Bard is perhaps best known for having introduced the [[Foley catheter]] in 1934.{{cn|date=April 2014}} In 2013, Bard began negotiations to settle nearly 30,000 legal claims related to implantable vaginal meshes made by the company.<ref name = nj>{{cite web | url = http://www.nj.com/business/index.ssf/2013/09/cr_bard_among_companies_negoti.html | title = C.R. Bard negotiating to settle thousands of lawsuits involving vaginal-mesh implants | publisher = NJ.com | accessdate = 15 April 2014}}</ref> |
||
==History== |
==History== |
||
Revision as of 16:19, 5 November 2015
 | This article needs to be updated. (April 2014) |
 | |
| Company type | Public |
|---|---|
| NYSE: BCR S&P 500 Component | |
| Founded | 1907 |
| Founder | Charles Russell Bard |
| Headquarters | Murray Hill, New Jersey, U.S. |
Area served | Worldwide |
Key people | Timothy M. Ring (Chairman) & (CEO) |
| Products | Vascular, Urology, Oncology, and Surgical Specialties |
| Revenue |  US$2.72B (FY 2010)[1] |
| US$730M (FY 2010)[1] | |
| US$509M (FY 2010)[1] | |
| Total assets | US$3.17B (FY 2010)[2] |
| Total equity |  US$1.63B (FY 2010)[2] |
Number of employees | 14,000 (2015) [3] |
| Website | http://www.crbard.com |
C. R. Bard, Inc., now branded simply as Bard, headquartered in Murray Hill, New Jersey, USA, is a leading multinational developer, manufacturer, and marketer of medical technologies in the fields of Vascular, Urology, Oncology, and Surgical Specialties. Bard markets its products and services worldwide to hospitals, individual health care professionals, extended care facilities, and alternate site facilities. An S&P 500 company with approximately 14,000 employees in 2015, Bard is perhaps best known for having introduced the Foley catheter in 1934.[citation needed] In 2013, Bard began negotiations to settle nearly 30,000 legal claims related to implantable vaginal meshes made by the company.[4]
History
C. R. Bard, Inc. was founded in New York City by Charles R. Bard in 1907. Bard's first business involved importing Gomenol, which was used to treat urinary discomfort.[5] The company formally incorporated in 1923, and three years later, in 1926, Charles R. Bard sold the company to John F. Willits and Edson L. Outwin for $18,000. Under Willits and Outwins, the company expanded into the catheter business, introducing the Foley catheter in 1934 and the America Woven Catheter in 1940.
In 1948, Bard's annual sales topped $1 million for the first time, and the company moved its headquarters from New York City to Summit, New Jersey. In 1954, a Bard scientist, Dr. DeBakey, developed the first arterial prosthesis.[citation needed] Three years later the company began selling Foley catheters that came in sterile packaging for the first time ever. Bard continued to innovate in the world of catheters, rolling out the Bipolar Temporary Pacing catheter in 1958 and the first latex balloon catheter in 1960. In 1961, Bard expanded beyond catheters, and began manufacturing products related to cardiology, radiology, and anesthesiology.
Bard went public in 1963 and was listed on the New York Stock Exchange in 1968. The company has introduced a variety of new health care products since that time. Its net sales first exceeded $1 billion in 1994. Around 2012, Bard acquired the company Lutonix.[6]
Illegal kickback settlement
In 2013, Bard agreed to pay $48.26 million to resolve kickback allegations filed against the company, relating to submitting false claims to Medicare. The complaint, filed in 2006, alleges Bard paid illegal kickbacks to both physicians and consumers.[7]
Products
Bard specializes in the manufacturing of vascular, urology, oncology and surgical specialty products.
References
- ^ a b c C.R. Bard (BCR) annual SEC income statement filing via Wikinvest.
- ^ a b C.R. Bard (BCR) annual SEC balance sheet filing via Wikinvest.
- ^ "[1].
- ^ "C.R. Bard negotiating to settle thousands of lawsuits involving vaginal-mesh implants". NJ.com. Retrieved 15 April 2014.
- ^ Anthony Hallett, Diane Hallett Entrepreneur magazine encyclopedia of entrepreneurs Page 27 - 1997 "Charles R. Bard ... During a trip to Europe, he encountered a medicine called Gomenol, derived from the eucalyptus tree, which relieved his ..."
- ^ George, John (September 5, 2012), "Intact Vascular raises $15.5M, developing stapler to replace stents", Philadelphia Business Journal, bizjournals.com, retrieved September 5, 2012
- ^ Tycko, Jonathan. "Top Whistleblower Settlements of 2013 – To Date". The National Law Review. Retrieved 6 November 2013.